Patents by Inventor Costas C. Loullis

Costas C. Loullis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cytokine restraining agents
    Patent number: 6245738
    Abstract: The present invention provides novel cytokine restraining agents, which limit or control the biological activity of cytokines. The invention also provides pharmaceutical compositions comprising a cytokine restraining peptide and methods of administering the pharmaceutical composition to a subject. The invention further provides methods for using the novel peptides to restrain cytokine activity in a subject.
    Type: Grant
    Filed: November 9, 1994
    Date of Patent: June 12, 2001
    Assignee: Trega Biosciences, Inc.
    Inventors: Mark J. Suto, Beverly E. Girten, Richard A. Houghten, Costas C. Loullis, Ronald R. Tuttle
  • Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
    Patent number: 5786332
    Abstract: The present invention relates to novel peptides that are potent cytokine restraining agents. In addition, the present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a cytokine restraining agent. Administration of such a cytokine restraining agent to a subject restrains, but does not necessarily suppress, cytokine activity completely. Thus, the present invention provides a method of restraining pathologically elevated cytokine activity in a subject. The invention also provides methods of treating disuse deconditioning and diseases mediated by nitric oxide and cytokines, such as diabetes and glomerulonephritis, a method of organ protection, a method of organ protection, and a method of reducing the negative side effects of cancer chemotherapy, such as nephrotoxicity.
    Type: Grant
    Filed: March 6, 1995
    Date of Patent: July 28, 1998
    Assignee: Trega Biosciences, Inc.
    Inventors: Beverly E. Girten, Richard A. Houghten, Costas C. Loullis, Mark J. Suto, Ronald R. Tuttle
  • Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
    Patent number: 5760001
    Abstract: The present invention relates to novel peptides that are potent cytokine restraining agents. In addition, the present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a cytokine restraining agent. Administration of such a cytokine restraining agent to a subject restrains, but does not necessarily suppress, cytokine activity completely. Thus, the present invention provides a method of restraining pathologically elevated cytokine activity in a subject. The invention also provides methods of treating disuse deconditioning and diseases mediated by nitric oxide and cytokines, such as diabetes and glomerulonephritis, a method of organ protection, a method of organ protection, and a method of reducing the negative side effects of cancer chemotherapy, such as nephrotoxicity.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: June 2, 1998
    Assignee: Trega Biosciences, Inc.
    Inventors: Beverly E. Girten, Richard A. Houghten, Costas C. Loullis, Mark J. Suto, Ronald R. Tuttle
  • Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
    Patent number: 5726156
    Abstract: The present invention relates to novel peptides that are potent cytokine regulatory agents. In addition, the present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a cytokine regulatory agent. Administration of such a cytokine regulatory agent to a subject can enhance or restrain cytokine activity. Thus, the present invention provides a method of regulating cytokine activity in a subject having a condition characterized by aberrant or altered cytokine activity. The invention also provides methods of treating such conditions, including, for example, disuse deconditioning, diseases mediated by nitric oxide and cytokines, adverse drug reactions, obesity, septic shock, and adverse side effects due to cancer chemotherapy or occurring as in response to organ transplantation.
    Type: Grant
    Filed: September 12, 1995
    Date of Patent: March 10, 1998
    Assignee: Trega Biosciences, Inc.
    Inventors: Beverly E. Girten, Ali Andalibi, Amaresh Basu, Patrick Fagan, Richard A. Houghten, Costas C. Loullis, Paul Omholt, Ronald R. Tuttle, Mark J. Suto, Patricia A. Weber
  • Cytokine restraining agents
    Patent number: 5420109
    Abstract: The present invention provides novel cytokine restraining agents, which limit or control the biological activity of cytokines. The invention also provides pharmaceutical compositions comprising a cytokine restraining peptide and methods of administering the pharmaceutical composition to a subject. The invention further provides methods for using the novel peptides to restrain cytokine activity in a subject.
    Type: Grant
    Filed: November 12, 1993
    Date of Patent: May 30, 1995
    Assignee: Houghten Pharmaceuticals, Inc.
    Inventors: Mark J. Suto, Beverly E. Girten, Richard A. Houghten, Costas C. Loullis, Ronald R. Tuttle